Failure to Renew Prescriptions for Gastroprotective Agents to Patients on Continuous Nonsteroidal Anti-inflammatory Drugs Increases Rate of Upper Gastrointestinal Injury

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 5, 2013, Pages

  Le Ray, Isabelle ^a,b   Barkun, Alan N ^c   Vauzelle Kervroëdan, Françoise ^d   Bardou, Marc ^a,b,e  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Ethypharm   (France)

^e Institut Médical de Génétique et d Immunologie   (France)

Author keywords

Bleeding; Protection; Stomach

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG USE; FEMALE; FRANCE; GASTRITIS; GENERAL PRACTITIONER; HUMAN; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRESCRIPTION; PROBABILITY SAMPLE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84876702027     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.016     Document Type: Article

References (39)

1. Paulose-Ram R., Hirsch R., Dillon C., et al. Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adults. Pharmacoepidemiol Drug Saf 2005, 14:257-266.
2. García Rodríguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:769-772.
3. Rahme E., Bardou M., Dasgupta K., et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007, 46:265-272.
4. García Rodríguez L.A., Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007, 132:498-506.
5. Laine L., Smith R., Min K., et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006, 24:751-767.
6. Rahme E., Barkun A., Nedjar H., et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008, 103:872-882.
7. Chang C.H., Lin J.W., Chen H.C., et al. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut 2011, 60:1372-1378.
8. Rahme E., Joseph L., Kong S.X., et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000, 43:917-924.
9. Lanas A., García-Rodríguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
10. Chan F.K., Abraham N.S., Scheiman J.M., et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008, 103:2908-2918.
11. Jones R., Rubin G., Berenbaum F., et al. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008, 121:464-474.
12. De Berardis G., Lucisano G., D'Ettorre A., et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012, 307:2286-2294.
13. Simon L.S., Weaver A.L., Graham D.Y., et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282:1921-1928.
14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
15. Langman M.J., Jensen D.M., Watson D.J., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929-1933.
16. Laine L., Curtis S.P., Cryer B., et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010, 32:1240-1248.
17. Lanas A., Garcia-Tell G., Armada B., et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011, 9:38.
18. lanas A., Polo-Tomás M., Roncales P., et al. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol 2012, 107:707-714.
19. Tielemans M.M., Eikendal T., Jansen J.B., et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010, 33:443-453.
20. Rahme E., Roussy J.P., Lafrance J.P., et al. Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada. Pharmacoepidemiol Drug Saf 2012, 21:420-427.
21. Miyamoto M., Haruma K., Okamoto T., et al. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J Gastroenterol Hepatol 2012, 27:372-377.
22. Abraham N.S., El-Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005, 129:1171-1178.
23. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
24. van Soest E.M., Sturkenboom M.C., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007, 26:265-275.
25. Abraham N.S., Hartman C., Castillo D., et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008, 103:323-332.
26. Sturkenboom M.C., Burke T.A., Tangelder M.J., et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003, 18:1137-1147.
27. Bouée S., Charlemagne A., Fagnani F., et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine 2004, 71:214-220.
28. van Soest E.M., Valkhoff V.E., Mazzaglia G., et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011, 60:1650-1659.
29. Rostom A., Moayyedi P., Hunt R., et al. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009, 29:481-496.
30. Scheiman J.M., Hindley C.E. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010, 32:667-677.
31. Burmester G., Lanas A., Biasucci L., et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011, 70:818-822.
32. El-Serag H.B., Fitzgerald S., Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol 2009, 104:2161-2167.
33. Doherty G.A., Cannon M.D., Lynch K.M., et al. Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do. J Clin Gastroenterol 2010, 44:e51-e56.
34. Dubois R.W., Melmed G.Y., Henning J.M., et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004, 19:197-208.
35. Lanza F.L., Chan F.K., Quigley E.M., et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
36. Laine L., Kivitz A.J., Bello A.E., et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012, 107:379-386.
37. Lanas A., Perez-Aisa M.A., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005, 100:1685-1693.
38. Coté G.A., Rice J.P., Bulsiewicz W., et al. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. Am J Gastroenterol 2008, 103:1097-1103.
39. De Groot N.L., Siersemal P.D., de Wit N.J., et al. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing a single tablet formulation with individual component strategies. Gut 2011, 60:A159.